RG7204 is a skin cancer pill which minimizes malignant melanomas, the most aggressive and deadliest form of skin cancer by 25 percent. RG7204 is also recognized as PLX4032 or RO5185426. The mutated BRAF protein that is found in around half of every cases of metastatic melanoma is restrained by RG7204. RG7204 will be accessible to patients later on this year or near the beginning of 2012.
RG7204 seek and obstruct the BRAF by leading the tumours to shrink. It will have a spectacular result on treatment of the people whose cancer has the BRAF mutation. It is the first melanoma therapy that has shown a major survival benefit. RG7204 is appropriate for the people with the BRAF V600 mutation, who had limited treatment alternatives.
James Larkin said, “This is an incredibly exciting breakthrough. Malignant melanoma is a very difficult disease to treat and with a growing incidence in younger people the results of this trial are very encouraging”. RG7204 had already impressed in phases I and II. In the phase III study, BRIM3 metastatic melanoma patients were randomly allotted to get either the melanoma treatment drug RG7204 or dacarbazine, a standard chemotherapy drug.
In BRIM3, the participants who got RG7204 lived longer without their disease getting worse. Rash, sensitivity to light, joint pain, hair loss, and fatigue are the common side effects in the trial. Serious side effects include several cases of cutaneous squamous cell carcinoma which is a type of skin cancer. Some patients also experienced enhanced liver enzymes that were mild and reversible.
In 15 to 34-year old people, skin cancer is the 2nd most common cancer which affects over 10,000 Britons every year. It is associated to sun exposure and affect twice as many women as men. “These results represent a paradigm shift in melanoma treatment and will change how we approach treatment of this disease,” said by Professor Marais.